CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for CytomX Therapeutics in a report released on Thursday, May 15th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will earn $0.02 per share for the quarter, down from their prior estimate of $0.20. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics' Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at ($0.02) EPS.
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The company had revenue of $50.92 million for the quarter, compared to the consensus estimate of $35.42 million. During the same quarter last year, the company posted $0.17 earnings per share.
Other equities research analysts also recently issued reports about the company. Wedbush reaffirmed an "outperform" rating and issued a $6.00 price target (up from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th. Piper Sandler raised their target price on CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. Finally, Wall Street Zen upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th.
Read Our Latest Research Report on CytomX Therapeutics
CytomX Therapeutics Price Performance
NASDAQ:CTMX traded up $0.10 during midday trading on Monday, reaching $2.23. The stock had a trading volume of 3,083,306 shares, compared to its average volume of 2,116,466. CytomX Therapeutics has a 1-year low of $0.40 and a 1-year high of $2.55. The firm's fifty day simple moving average is $0.97 and its 200-day simple moving average is $0.93. The stock has a market capitalization of $179.78 million, a P/E ratio of 13.12 and a beta of 1.11.
Institutional Investors Weigh In On CytomX Therapeutics
A number of institutional investors have recently added to or reduced their stakes in CTMX. JPMorgan Chase & Co. grew its holdings in shares of CytomX Therapeutics by 288,736.3% during the 4th quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company's stock worth $836,000 after purchasing an additional 811,349 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of CytomX Therapeutics by 32.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,346,800 shares of the biotechnology company's stock worth $1,387,000 after purchasing an additional 331,800 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of CytomX Therapeutics by 76.2% during the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 27,800 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in CytomX Therapeutics by 13.9% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company's stock worth $1,422,000 after buying an additional 169,000 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in CytomX Therapeutics during the fourth quarter worth $35,000. 67.77% of the stock is owned by institutional investors and hedge funds.
About CytomX Therapeutics
(
Get Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
See Also
Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
